

76. Takenaka K, Eto T, Nagafuji K, Kamezaki K, Matsuo Y, Yoshimoto G, Harada N, Yoshida M, Henzan H, Takase K, Miyamoto T, Akashi K, Harada M, Teshima T: Oral valganciclovir as preemptive therapy is effective for cytomegalovirus infection in allogeneic hematopoietic stem cell transplantation. *Int J Hematol* (2009) 89(2): 231-237
77. Kohno K, Nagafuji K, Tsukamoto H, Horiuchi T, Takase K, Aoki K, Henzan H, Kamezaki K, Takenaka K, Miyamoto T, Teshima T, Harada M, Akashi K.: Infectious complications in patients receiving autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune disease. *Transpl Infect Dis.* (2009) 11(4): 318-323
78. Abe Y, Ito T, Baba E, Nagafuji K, Kawabe K, Choi I, Arita Y, Miyamoto T, Teshima T, Nakano S, Harada M: Nonmyeloablative allogeneic hematopoietic stem cell transplantation as immunotherapy for pancreatic cancer. *Pancreas.* (2009) 38(7):815-819
79. Yamauchi T, Mori Y, Miyamoto T, Kamezaki K, Aoki T, Yamamoto A, Takenaka K, Iwasaki H, Harada N, Nagafuji K, Teshima T, Akashi K.: Second unrelated cord blood transplantation using a reduced conditioning regimen combined with gemtuzumab ozogamicin in patients with relapsed acute myelogenous leukemia. *Int J Hematol.* (2009) 90(3): 416-420
80. Shima T, Yoshimoto G, Miyamoto T, Yoshida S, Kamezaki K, Takenaka K, Iwasaki H, Harada N, Nagafuji K, Teshima T, Shimono N, Akashi K.: Disseminated tuberculosis following second unrelated cord blood transplantation for acute myelogenous leukemia. *Transplant Infect Dis.* (2009) 11(1):75-77
81. Matsuo Y, Kamezaki K, Takeishi S, Takenaka K, Eto T, Nonami A, Miyamoto T, Iwasaki H, Harada N, Nagafuji K, Teshima T, Akashi K.: Encephalomyelitis mimicking multiple sclerosis associated with chronic graft-versus-host disease after allogeneic bone marrow transplantation. *Intern Med.* (2009) 48(16):1453-1456
82. Mori Y, Aoki T, Takenaka K, Yamauchi T, Yamamoto A, Kamezaki K, Iwasaki H, Harada N, Miyamoto T, Nagafuji K, Teshima T, Akashi K.: Successful treatment of refractory advanced nasal NK/T cell lymphoma with unrelated cord blood stem cell transplantation incorporating focal irradiation. *Int J Hematol.* (2009) 91(1): 107-111
83. Toubai T, Shono Y, Nishihira J, Ibata M, Suigita J, Kato N, Ohkawara T, Tone S, Lowler K, Ota S, Tanaka J, Asaka M, Reddy P, Imamura M.: Serum macrophage migration inhibitory factor (MIF) levels after allogeneic hematopoietic stem cell transplantation. *Int J Lab Hematol.* (2009) 31:161-168

84. Tsutsumi Y, Ichiki K, Shiratori S, Kawamura T, Tanaka J, Asaka M, Imamura M, Masauzi N. : Changes in hepatitis C virus antibody titer and viral RNA load in non-Hodgkin's lymphoma patients after rituximab chemotherapy. *Int J Lab Hematol.* (2009) 31:468-470
85. Tsutsumi Y, Shigematsu A, Hashino S, Tanaka J, Chiba K, Masauzi N, Kobayashi H, Kurosawa M, Iwasaki H, Morioka M, Asaka M, Imamura M. : Analysis of reactivation of hepatitis B virus in the treatment of B cell non-Hodgkin's lymphoma in Hokkaido. *Ann Hematol.* (2009)88: 375-377
86. Shigematsu A, Yasumoto A, Yamamoto S, Sugita J, Kondo T, Onozawa M, Kahata K, Endo T, Ota S, Sato N, Takahata M, Okada K, Tanaka J, Hashino S, Nishio M, Koike T, Asaka M, Imamura M. : Regimen-related mucosal injury of the gut increased the incidence of CMV disease after allogeneic bone marrow transplantation. *Biol Blood Marrow Transplant.* (2009) 15:679-685
87. Toubai T, Shono Y, Tone S, Ibata M, Kato N, Malter C, Lowler KP, Ota S, Tanaka J, Asaka M, Imamura M. : Serum soluble tumor necrosis factor-related apoptosis-inducing ligand level after allogeneic hematopoietic cell transplantation. *Leuk Lymphoma.* (2009)50:844-847
88. Onozawa M, Hashino S, Haseyama Y, Hirayama Y, Iizuka S, Ishida T, Kaneda M, Kobayashi H, Kobayashi R, Koda K, Kurosawa M, Masauji N, Matsunaga T, Mori A, Mukai M, Nishio M, Noto S, Ota S, Sakai H, Suzuki N, Takahashi T, Tanaka J, Torimoto Y, Yoshida M, Fukuhara T. : Incidence and risk of postherpetic neuralgia after varicella zoster virus infection in hematopoietic cell transplantation recipients: hokkaido hematology study group. *Biol Blood Marrow Transplant.* (2009)15: 724-729
89. Takahara M, Tsuji G, Ishii N, Dainichi T, Hashimoto T, Kohno K, Kamezaki K, Nagafuji K, Takeuchi S, Moroi Y, Furue M. Mucous membrane pemphigoid with antibodies to the beta(3) subunit of Laminin 332 in a patient with acute myeloblastic leukemia and graft-versus-host disease. *Dermatology.* 2009;219:361-364.
90. Narimatsu H, Watanabe M, Kohno A, Sugimoto K, Kuwatsuka Y, Uchida T, Murata M, Miyamura K, Morishita Y. : High incidence of graft failure in unrelated cord blood transplantation using a reduced-intensity preparative regimen consisting of fludarabine and melphalan. *Bone Marrow Transplant.* (2008)41:753-756
91. Inamoto Y, Suzuki R, Kuwatsuka Y, Yasuda T, Takahashi T, Tsujimura A, Sugimoto K, Oba T, Terakura S, Atsuta Y, Murata M, Ito M, Kodera Y, Miyamura K. : Long-term outcome after bone marrow transplantation for aplastic anemia using cyclophosphamide and total lymphoid irradiation as conditioning

- regimen. Biol Blood Marrow Transplant. (2008) 14:43-49
92. Kimura F, Sato K, Kobayashi S, Ikeda T, Sao H, Okamoto S, Miyamura K, Mori S, Akiyama H, Hirokawa M, Ohto H, Ashida H, Motoyoshi K. : Impact of ABO-blood group incompatibility on the outcome of recipients of bone marrow transplants from unrelated donors in the Japan Marrow Donor Program. Haematologica. (2008)93:1686-1693
 93. Kohno A, Morishita Y, Iida H, Yanada M, Uchida T, Hamaguchi M, Sawa M, Sugiura I, Yamamoto K, Mizuta S, Sao H, Naoe T, Miyamura K. : Hematopoietic stem cell transplantation for acute promyelocytic leukemia in second or third complete remission: a retrospective analysis in the Nagoya Blood and Marrow Transplantation Group. Int J Hematol. (2008)87:210-216
 94. Nagamura-Inoue T, Kai S, Azuma H, Takanashi M, Isoyama K, Kato K, Takahashi S, Taniguchi S, Miyamura K, Aoki K, Hidaka M, Nagamura F, Tojo A, Fang X, Kato S. : Unrelated cord blood transplantation in CML: Japan Cord Blood Bank Network analysis. Bone Marrow Transplant. (2008)42:241-251
 95. Sugimoto K, Murata M, Onizuka M, Inamoto Y, Terakura S, Kuwatsuka Y, Oba T, Miyamura K, Kodera Y, Naoe T. : Decreased risk of acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation in patients with the 5,10-methylenetetrahydrofolate reductase 677TT genotype. Int J Hematol. (2008)87:451-458
 96. Sugimoto K, Narimatsu H, Kawase T, Iida H, Watanabe M, Kohno A, Kuwatsuka Y, Uchida T, Hamaguchi M, Terakura S, Naoe T, Matsuo K, Murata M, Sawa M, Miyamura K, Morishita Y. : Clinical characteristics of chronic graft-versus-host disease following umbilical cord blood transplantation for adults. Bone Marrow Transplant. (2008)41:729-736
 97. Yamada MF, Miyamura K, Fujiwara T, Kohata K, Okitsu Y, Ohguchi H, Yamamoto J, Yokoyama H, Tomiya Y, Ishizawa K, Kameoka J, Harigae H. : Myeloablative cord blood transplantation for adults with hematological malignancies using tacrolimus and short-term methotrexate for graft-versus-host disease prophylaxis: single-institution analysis. Transplant Proc. (2008)40:3637-3642
 98. Kawase T, Matsuo K, Kashiwase K, Inoko H, Saji H, Ogawa S, Kato S, Sasazuki T, Kodera Y, Morishima Y. : HLA mismatch combinations associated with decreased risk of relapse: mplications for molecular mechanism. Blood. (2008)
 99. Yabe T, Matsuo K, Hirayasu K, Kashiwase K, Kawamura-Ishii S, Tanaka H, Ogawa A, Takanashi M, Satake M, Nakajima K, Tokunaga K, Inoko H, Saji H, Ogawa S, Juji T, Sasazuki T, Kodera Y, Morishima Y; Japan Marrow Donor Program: Donor

- killer immunoglobulin γ -like receptor (KIR) genotype-patient cognate KIR ligand combination and antithymocyte globulin preadministration are critical factors in outcome of HLA-C-KIR ligand-mismatched T cell-replete unrelated bone marrow transplantation. *Biol Blood Marrow Transplant.* (2008)14(1):75-87
100. Torikai H, Akatsuka Y, Yatabe Y, Morishima Y, Kodera Y, Kuzushima K, Takahashi T.: Aberrant expression of BCL2A1-restricted minor histocompatibility antigens in melanoma cells: application for allogeneic transplantation. *Int J Hematol.* (2008) 87(5):467-73
101. Nakane T, Nakamae H, Kamoi H, Koh H, Takeoka Y, Sakamoto E, Kanashima H, Nakamae M, Ohta K, Terada Y, Koh K-R, Yamane T, Hino M.: Prognostic value of serum surfactant protein D level prior to transplant for the development of bronchiolitis obliterans syndrome and idiopathic pneumonia syndrome following allogeneic hematopoietic stem cell transplantation. *Bone Marrow Transplant.* (2008)42(1):43-49
102. Mori T, Hasegawa K, Okabe A, Tsujimura N, Kawata Y, Yashima T, Kobayashi N, Kondo S, Aisa S, Kato J, Tsunoda K, Nagai T, Nakagawa T, Shigematsu N, Kubo A, Ikeda Y, Okamoto S.: Efficacy of mouth rinse in preventing oral mucositis in patients receiving high-dose cytarabine for allogeneic hematopoietic stem cell transplantation. *International Journal of Hematology* 88(5): 583-587 (2008)
103. Mori T, Aisa Y, Yajima T, Shimizu T, Kato J, Nakazato T, Hibi T, Ikeda Y, Okamoto S.: Esophageal varices and portal hypertensive gastropathy associated with hepatic veno-occlusive disease after allogeneic hematopoietic stem cell transplantation. *Int J Hematol* (2008)87: 231-232
104. Aisa Y, Mori T, Yamamoto K, Takae Y, Kato J, Ikeda Y, Okamoto S.: Development of varicella after allogeneic cord blood transplantation in a varicella zoster virus seropositive patient. *Scandinavian Journal of Infectious Diseases.* (2008) 40: 684-685
105. Wang Y, Ogawa Y, Dogru M, Kawai M, Tatematsu Y, Uchino M, Okada N, Igarashi A., Kujira A, Fujishima H, Okamoto S, Shimazaki J, Tsubota K.: Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease. *Bone Marrow Transplantation.* (2008) 41: 293-302
106. Morizane R, Sasamura H, Minakuchi H, Takae Y, Kikuchi H, Yoshiya N, Hashiguchi A, Konishi K, Okamoto S, Itoh H.: A case of atypical POEMS syndrome without polyneuropathy. *Eur J Haematol.* (2008) 80 (5): 452-455
107. Mori T, Aisa Y, Watanabe R,

- Yamazaki R, Kato J, Shimizu T, Shigematsu N, Kubo A, Yajima T, Hibi T, Ikeda Y, Okamoto S.: Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine. *Biology of Blood and Marrow Transplantation.* (2008) 14: 651-657
108. Mori T, Watanabe M, kurotori-Sotome T, Ito C, Yamada K, Yashima T, Kobayashi N, Kondo S, Aisa Y, Kato J, Ogawa Y, Tsubota K, Shigematsu N, Kubo A, Ikeda Y, Okamoto S.: Reduced efficacy of topical corticosteroid in preventing cytarabine-induced kerato-conjunctivitis in patients receiving high-dose cytarabine and total body irradiation for allogeneic hematopoietic stem cell transplantation. *Bone Marrow Transplantation.* (2008) 42: 197-199
109. Aisa Y, Mori T, Tanikawa A, Takae Y, kato J, Ikeda Y, Okamoto S.: Demodicidosis as a cause of facial eruption developing early after allogeneic hematopoietic stem cell transplantaion. *Transplantation International.* (2008) 21(12):1192-1193
110. Oshima K, Kanda Y, Yamashita T, Takahashi S, Mori T, Nakaseko C, Fujimaki K, Yokota A, Fujisawa S, Matsushima T, Fujita H, Sakura T, Okamoto S, Maruta A, Sakamaki H.; Kanto Study Group for Cell Therapy. : Central nervous system relapse of leukemoia after allogeneic hematopoietic stem cell transplantation. *Biology of Blood and Marrow Transplantation.* (2008) 14(10): 1100-1107
111. Kimura F, Sato K, Kobayashi S, Ikeda T, Sao H, Okamoto S, Miyakoshi K, mori S, Akiyama H, Hirokawa M, Ohto H, Ashida H, Motoyoshi K.; Japan marrow Donor Program. Impact of ABO blood group incompatibility on the outcome of recipients of bone marrow transplants from unrelated donors in the Japan Marrow Donor Program. : *Hematologica.* (2008) 93(11): 1686-1693
112. Aisa Y, Mori T., Yamamoto K, Takae Y, Kato J, Ikeda Y, Okamoto S.: Development of varicella after allogeneic cord blood transplantation in a varicella zoster virus seropositive patient. *Scandinavian Journal of Infectious Disease.* (2008) 40(8): 684-685
113. Yamasaki S, Heike Y, Mori S, Fukuda T, Maruyama D, Kato R, Usui E, Koido K, Kim S, Tanosaki R, Tobinai K, Teshima T, Takaue Y: Infectious complications in chronic graft-versus-host disease: a retrospective study of 145 recipients of allogeneic hematopoietic stem cell transplantation with reduced- and conventional-intensity conditioning regimens. *Transplant Infect Dis.* (2008) 10(4): 252-259

114. Eto M, Kamiryo Y, Takeuchi A, Hirano M, Tatsugami K, Harada M, Kiyoshima K, Hamaguchi M, Teshima T, Tsuneyoshi M, Yoshikai Y.: Posttransplant administration of cyclophosphamide and donor lymphocyte infusion induces potent antitumor immunity to solid tumor. Clin Cancer Res. (2008) 14(9):2833-2840
115. Kim S-W, Matsuo K, Fukuda T, Hara M, Matsue K, Taniguchi S, Eto T, Tanimoto M, Wake A, Hatanaka K, Nakao S, Ishida Y, Harada M, Utsunomiya A, Imamura M, Kanda Y, Sunami K, Kawano F, Takaue Y, Teshima T.: Reduced-intensity unrelated donor bone marrow transplant for hematologic malignancies. Int J Hematol. (2008) 88(3): 324-330
116. Sumida Y, Nakamura K, Kanayama K, Akiho H, Teshima T, Takayanagi R.: Preparation of functionally preserved CD4+ CD25high regulatory T cells from leukapheresis products from ulcerative colitis patients, which are applicable to regulatory T cell-transfer therapy. Cytotherapy. (2008) 10(7): 698-710
117. Shima T, Yoshimoto G, Nonami A, Yoshida S, Kamezaki K, Iwasaki H, Takenaka K, Miyamoto T, Harada N, Teshima T, Akashi K, Nagafuji K.: Successful treatment of parainfluenza virus 3 pneumonia with oral ribavirin and methylprednisolone in a bone marrow transplant recipient. Int J Hematol. (2008) 88(3):336-340
118. Shigematsu A, Kondo T, Yamamoto S, Sugita J, Onozawa M, Kahata K, Endo T, Shiratori S, Ota S, Obara M, Wakasa K, Takahata M, Takeda Y, Tanaka J, Hashino S, Nishio M, Koike T, Asaka M, Imamura M.: Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total body irradiation for adult patients with acute lymphoblastic leukemia. Biol Blood Marrow Transplant. (2008)14:568-575
119. Onozawa M, Hashino S, Morita R, Takahata M, Shigematsu A, Kahata K, Kondo T, Tanaka J, Imamura M, Asaka M.: HB vaccination in the prevention of viral reactivation in allogeneic hematopoietic stem cell transplantation recipients with previous HBV infection. Biol Blood Marrow Transplant. (2008)14:1226-1230
120. Shiratori S, Yasumoto A, Tanaka J, Shigematsu A, Yamamoto S, Nishio M, Hashino S, Morita R, Takahata M, Onozawa M, Kahata K, Kondo T, Ota S, Wakasa K, Sugita J, Koike T, Asaka M, Kasai M, Imamura M.: A retrospective analysis of allogeneic hematopoietic stem cell transplantation for adult T cell leukemia/lymphoma (ATL): clinical impact of graft-versus-leukemia/lymphoma effect. Biol Blood Marrow Transplant. (2008)14:817-823
121. Kondo T, Mori A, Darmanin S, Hashino S, Tanaka J, Asaka M.: The seventh

- pathogenic fusion gene FIP1L1-RARA was isolated from a t(4;17)-positive Acute Promyelocytic Leukemia. *Haematologica*. (2008)93:1414-1416
122. Sugita J, Iwao N, Tanaka J, Kato N, Shiratori S, Wakasa K, Shigematsu A, Toubai T, Takahata M, Kondo T, Asaka M, Imamura M.: T cell receptor excision circle (TREC) levels in CD94-expressing CD8 T Cells during graft-versus-host disease. *Leukemia Lymphoma*. (2008) 49:1306-1310
123. Sugita J, Tanaka J, Hashimoto A, Shiratori S, Yasumoto A, Wakasa K, Kikuchi M, Shigematsu A, Miura Y, Tsutsumi Y, Kondo T, Asaka M, Imamura M. Influence of conditioning regimens and stem cell sources on donor-type chimerism early after stem cell transplantation. *Ann Hematol*. (2008)87: 1003-1008
124. Toubai T, Hirate D, Shono Y, Ota S, Ibata M, Mashiko S, Sugita J, Shigematsu A, Miura Y, Kato N, Umehara S, Kahata K, Tsutsumi Y, Iwao N, Toyoshima N, Tanaka J, Asaka M, Imamura M.: Chimerism and T-cell receptor repertoire analysis after unrelated cord blood transplantation with a reduced-intensity conditioning regimen following autologous stem cell transplantation for multiple myeloma. *Int J Lab Hematol*. (2008)30:75-81
125. Yoshimi A, Izutsu K, Takahashi M, Kako S, Oshima K, Kanda Y, Motokura T, Chiba S, Momose T, Ohtomo K, Kurokawa M. Conventional allogeneic hematopoietic stem cell transplantation for lymphoma may overcome the poor prognosis associated with a positive FDG-PET scan before transplantation. *Am J Hematol*. (2008)83:477-481
126. Kanda Y, Omuro Y, Baba E, Oshima K, Nagafuji K, Heike Y, Takaue Y, Sasaki T, Sakamaki H, Harada M. Allo-SCT using reduced-intensity conditioning against advanced pancreatic cancer: a Japanese survey. *Bone Marrow Transplantation*. 2008;42:99-103.

学会発表

国内

1. 宮村耕一. より良い移植医療・より良い治癒～移植医療を支える人々, 医療システム, 32 回日本造血細胞移植学会総会 浜松 2010. 2
2. 村瀬未帆, 西田徹也, 鬼塚真仁, 稲本賢弘, 杉本恭子, 今橋伸彦, 村田 誠, 宮村耕一, 小寺良尚, 猪子英俊, 直江知樹. 同種造血幹細胞移植におけるCytotoxic T-Lymphocyte Antigen 4 (CTLA-4) 遺伝子多型の影響 第32回日本造血細胞移植学会総会 浜松2010. 2
3. 渡邊慶介, 西脇聡史, 稲本賢弘, 佐尾 浩, 坂巻 壽, 黒川峰夫, 福田隆浩, 小川啓恭, 森島泰雄, 熱田由子, 宮村耕一 成人Ph (-)ALL に対する第一寛解期での血縁者間と非血縁者間同種造血幹細胞移植では生存率は同等であるがリスク因子は異なる. 第8回日本臨床腫瘍学術集会 東京都 2010. 3

4. 小澤幸泰, 小山大輔, 小野寺晃一, 後藤辰徳, 瀬戸愛花, 渡邊慶介, 今橋伸彦, 塚本祥吉, 宮村耕一. :Ph 陽性急性リンパ性白血病に対する同種造血細胞移植施行群とイマチニブ併用化学療法継続群の治療成績の検討. 第71回日本血液学会 京都府 2009.10
 5. 宮村 耕一 シンポジウム4 造血細胞移植・採取 骨髄移植 日本輸血・細胞治療学会 2009.5
 6. ・塚本祥吉, 西脇聡史, 後藤辰徳, 瀬戸愛花, 渡邊慶介, 今橋伸彦, 榎葉誠, 小澤幸泰, 宮村耕一. 当院における悪性リンパ腫に対する同種造血幹細胞移植の成績. 第31回日本造血細胞移植学会総会 札幌 2009.2
 7. ・今橋伸彦, 伊藤雅文, 池口美代子, 後藤辰徳, 瀬戸愛花, 渡邊慶介, 塚本祥吉, 西脇聡史, 榎葉誠, 小澤幸泰, 宮村耕一. 急性骨髄性白血病に対する同種造血幹細胞移植後早期の CD8+細胞及び CD56+細胞による抗白血病効果の検討. 第31回日本造血細胞移植学会総会 札幌 2009.2
 8. 瀬戸愛花, 後藤辰徳, 渡邊慶介, 今橋伸彦, 塚本祥吉, 西脇聡史, 小澤幸泰, 宮村耕一
同種造血幹細胞移植生着後の非感染性発熱症例の検討-GVHD との関連について. 第31回日本造血細胞移植学会総会 札幌 2009.2
 9. 宮村耕一. 非血縁 PBSCH/T の必要性(患者側からとドナー側から, 海外経験も含めて) 第31回日本造血細胞移植学会総会 札幌 2009.2
 10. 日野雅之. 非血縁者間末梢血幹細胞移植. 第31回日本アフェレーシス学会 札幌 2009.10
 11. 田中淳司. NK 細胞受容体発現細胞と同種造血細胞移植療法_第31回 日本造血細胞移植学会総会 札幌 2009.2
 12. 田中淳司. 抗腫瘍免疫におけるNK細胞受容体発現細胞の役割. 第19回 日本サイトメトリー学会 松江 2009.6
 13. 中根孝彦, 中前博久, 相本瑞樹, 阪本親彦, 赤澤結貴, 和田恵里, 康 秀男, 武岡康信, 寺田芳樹, 高 起良, 山根孝久, 日野雅之. 心機能低下5症例に対する骨髄非破壊的同種造血幹細胞移植 (RIST) 後の心機能および自律神経機能の解析. 第30回日本造血細胞移植学会総会 大阪 2008.2
- 海外
1. Miyamura, K. Indication of HSCT for AML Carrying t(8;21); From the Database of JSHCT and JSHCT and JALSG. Educational Session (I) 14th Congress of the Asia-Pacific Blood and Marrow Transplantation August 27-29, 2009
 2. Teshima T. Current status and future prospects of hematopoietic stem cell transplantation in Japan. Chinese Marrow Donor Program Transplant Hospital Technical Conference. Wuhan, China. May 20-21, 2010 (Invited speaker)
 3. Shigematsu A, Tanaka J, Suzuki R, Kawase T, Akiyama H, Fukuda T, Kumano K, Yoshida F, Kanamori H, Naoki Kobayashi^{10*}, Fukuhara T, Imamura M.: Superior Outcomes Using Medium-Dose VP-16/CY/TBI to CY/TBI as a

- Conditioning Regimen for Allogeneic Stem Cell Transplantation for Adult Patients with Acute Lymphoblastic Leukemia. 51st Annual Meeting of American Society of Hematology (ASH) New Orleans, U.S.A December 5-8, 2009
4. Teshima T. Pathophysiologic mechanisms of GVHD. New Perspectives in Cancer Research. Ulsan, Korea. Novemver 14, 2009 (Invited speaker)
 5. Kodera Y. Miyamura, K, Nagafuji, K., Hino, M., Kim, S., Suzuki, R. Related Donor Outcomes from the Japanese registry—the Importance of Pre-Registration System 2009 Blood and Marrow Transplantation Tandem Meetings Tampa, Florida February 11-15, 2009
 6. Kodera Y., Yoshimi A, Suzuki R, Atsuta Y, Chan LL, Li A., Tan, W., Hwang Y, Binh, T. Chiou, T. Ghavamzadeh, L. Dao-Pei, L. Chen P-M, on behalf of APBMT. Current trend of haematopoietic stem cell transplantation in Asia;a report from Asia-Pacific Blood and Marrow Transplantation Group (APBMT) 34th Annual Meeting of the European Group for Blood and Marrow Transplantation. Florence, Ital • March 30-April 2, 2008
 7. •Miyamura K, Tsujimura A, Kuwatsuka Y, Sugimoto K, Inamoto Y, Oba T, Terakura S, Kodera Y High Dose of Corticosteroidease Therapy during the first 100 days Increase Adenovirus Infection Following Allogeneic Hematopoietic Stem Cell Transplantation. The 13 th Congress of the Asia Pacific Bone Marrow Transplantation Tapei , Taiwan April 25-27, 2008
 8. Teshima T. Immunobiology of chronic GVHD. 2008 BMT Tandem Meetings. San Diego, CA, USA. Feb 13-17, 2008 (Invited speaker)
- H. 知的所有権の出願・取得状況（予定を含む）
- 1 特許取得
なし
 - 2 実用新案登録
なし
 - 3 その他
なし


Ⅱ. 研究成果の刊行に関する一覧表

発表者氏名	論文タイトル名	発表誌名	巻名	ページ	出版年
Shigematsu A, Kondo T, Yamamoto S, Sugita J, Onozawa M, Kahata K, Endo T, Shiratori S, Ota S, Obara M, Wakasa, Takahata M, Takeda Y, Tanaka J, Hashino S, Nishio M, Koie T, Asaka M, Imamura M.	Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total body irradiation for adult patients with acute lymphoblastic leukemia	Biol Blood Marrow Transplant.	14	568-575	2008
Nakane T, Nakamae H, Koh H, Nakamae M, Aimoto R, Terada Y, Koh KR, Yamane T, Hino M.	Heart rate variability during and after peripheral blood stem cell leukapheresis in autologous transplant patients and allogeneic transplant donors.	International Journal of Hematology	91	478-484	2010
Hishizawa M, Kanda J, Utsumomiya A, Taniguchi S, Eto T, Moriuchi Y, Tanosaki R, Kawano F, Miyazaki Y, Masuda M, Nagafuji K, Hara M, Takanashi M, Kai S, Atsuta Y, Suzuki R, Kawase T, Matsuo K, Nagamura-Inoue T, Kato S, Sakamaki H, Morishima Y, Okamura J, Ichinohe T, Uchiyama T.	Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study.	blood	116	1369-1376	2010
Atsuta Y, Suzuki R, Nagamura-Inoue T, Taniguchi S, Takahashi S, Kai S, Sakamaki H, Kouzai Y, Kasai M, Fukuda T, Azuma H, Takanashi M, Okamoto S, Tsuchida M, Kawa K, Morishima Y, Kodera Y, Kato S; Japan Cord Blood Bank Network.	Disease-specific analyses of unrelated cord blood transplantation compared with unrelated bone marrow transplantation in adult patients with acute leukemia.	Blood.	113 (8)	1631-8	2009

Nishiwaki S, Terakura S, Ito M, Goto T, Seto A, Watanabe K, Yanagisawa M, Imahashi N, Tsukamoto S, Shimba M, Ozawa Y, <u>Miyamura K</u> .	Impact of macrophage infiltration of skin lesions on survival after allogeneic stem cell transplantation: a clue to refractory graft-versus-host disease.	Blood	114	3113-3116	2009
Kuwatsuka Y, <u>Miyamura K</u> , Suzuki R, Kasai M, Maruta A, Ogawa H, Tanosaki R, Takahashi S, Koda K, Yago K, Atsuta Y, Yoshida T, Sakamaki H, Kodera Y.	Hematopoietic stem cell transplantation for core binding factor acute myeloid leukemia: t(8;21) and inv(16) represent different clinical outcomes.	Blood	113	2096-2103	2009
Nishiwaki S, Inamoto Y, Sakamaki H, Kurokawa M, Iida H, Ogawa H, Fukuda T, Ozawa Y, Kobayashi N, Kasai M, Mori T, Iwato K, Yoshida T, Onizuka M, Kawa K, Morishima Y, Suzuki R, Atsuta Y, <u>Miyamura K</u> .	Allogeneic stem cell transplantation for Philadelphia adult chromosome-negative acute lymphocytic leukemia: comparable survival rates but different risk factors between related and unrelated transplantation in first complete remission.	Blood	116	4368-4375	2010
<u>Kim SW</u> , Matsuo K, Fukuda T, Hara M, Matsue K, Taniguchi S, Eto T, Tanimoto M, Wake A, Hatanaka K, Nakao S, Ishida Y, Harada M, Utsumiya A, Imamura M, Kanda Y, Sunami K, Kawano F, Takaue Y, Teshima T.	Reduced-intensity unrelated donor bone marrow transplantation for hematologic malignancies.	International Journal of Hematology	88	324-330	2008
Asakura S, Hashimoto D, Takashima S, Sugiyama H, Maeda Y, Akashi K, Tanimoto M, <u>Teshima T</u>	Alloantigen expression on non-hematopoietic cells reduces graft-versus-leukemia effects in mice	J Clin Invest	120	2370-2378	2010

<p>Oh I, Ozaki K, Meguro A, Hatanaka K, Kadowaki M, Matsui H, Tatara R, Sato K, Iwakura Y, Nakae S, Sudo K, <u>Teshima T</u>, Leonard WJ, Ozawa K</p>	<p>Altered effector CD4+ T cell function in IL-21R-/- CD4+ T cell-mediated graft-versus-host disease</p>	<p>J Immunol</p>	<p>185</p>	<p>1441-1444</p>	<p>2010</p>
<p>Gratwohl A, Baldomero H, Aljurf M, Pasquini MC, Bouzas LF, Yoshimi A, Szer J, Lipton J, Schwendener A, Gratwohl M, Frauendorfer K, Niederwieser D, Horowitz M, <u>Kodera Y</u>;</p>	<p>Hematopoietic stem cell transplantation: a global perspective. Worldwide Network of Blood and Marrow Transplantation.</p>	<p>JAMA.</p>	<p>303(16)</p>	<p>303(16):</p>	<p>2010</p>

Ⅲ. 研究成果の刊行物



Excellent Outcome of Allogeneic Hematopoietic Stem Cell Transplantation Using a Conditioning Regimen with Medium-Dose VP-16, Cyclophosphamide and Total-Body Irradiation for Adult Patients with Acute Lymphoblastic Leukemia

Akio Shigematsu,¹ Takeshi Kondo,² Satoshi Yamamoto,³ Junichi Sugita,¹ Masahiro Onozawa,² Kaoru Kabata,² Tomoyuki Endo,³ Soichi Shiratori,¹ Shuichi Ota,² Masato Obara,³ Kentaro Wakasa,¹ Mutsumi Takabata,² Yukari Takeda,³ Junji Tanaka,¹ Satoshi Hashino,² Mitsufumi Nishio,³ Takao Koike,³ Masahiro Asaka,² Masahiro Imamura¹

¹Department of Hematology and Oncology, ²Department of Gastroenterology and Hematology, and ³Department of Medicine II, Hokkaido University Graduate School of Medicine, Sapporo, Japan

Correspondence and reprint requests: Akio Shigematsu, MD, Hematology and Oncology, Hokkaido University Graduate School of Medicine, Kita-15 Nishi-7, Kita-ku, Sapporo, Hokkaido, 060-8638, Japan (e-mail: shigemap@r9.dion.ne.jp).

Received January 8, 2008; accepted February 26, 2008

ABSTRACT

We retrospectively evaluated the outcomes of 37 adult patients with acute lymphoblastic leukemia (ALL) undergoing allogeneic hematopoietic stem cell transplantation (allo-SCT) conditioned with medium-dose VP-16 (VP, 30 mg/kg), cyclophosphamide (CY, 120 mg/kg), and fractionated total-body irradiation (TBI, 12 Gy) (medium-dose VP/CY/TBI). The median age of the patients was 26 years. Thirteen patients underwent transplantation from HLA-matched related donors (MRD), 18 patients underwent transplantation from HLA-matched unrelated donors (MUD), and 6 patients underwent transplantation from HLA-mismatched donors (MMD). Thirty-two patients received bone marrow and 4 patients received peripheral blood stem cells. Ten patients were Philadelphia chromosome-positive (Ph⁺) and 35 patients were in complete remission (CR) at transplantation. All of the patients achieved engraftment, and grade 3 organ toxicity before engraftment occurred in 27 patients. Grade II-III acute graft-versus-host disease (GVHD) and chronic GVHD (cGVHD) occurred in 15 and 18 patients, respectively. No patient developed grade IV acute GVHD (aGVHD) or died of GVHD. At median follow-up of 35.1 months, 32 patients were alive and all Ph⁺ patients were alive. Three patients died of relapse and 2 died of transplant-related mortality (TRM). The actuarial 3-year overall survival (OS) rate, relapse rate, and TRM rate were 89.2%, 8.1%, and 5.4%, respectively. Non-CR at transplantation, MRD, and no aGVHD were significant adverse prognostic factors for survival. Medium-dose VP/CY/TBI for adult ALL patients was associated with lower relapse rate and no increase in toxicity, resulting in better survival.

© 2008 American Society for Blood and Marrow Transplantation

KEY WORDS

VP-16 • Acute lymphoblastic leukemia • Adult • Hematopoietic stem cell transplantation
• Conditioning regimen

INTRODUCTION

Although complete remission (CR) has been induced by multiagent chemotherapies in the majority of patients with acute lymphoblastic leukemia (ALL), prognosis for adult ALL has not been satisfactory due to a high rate of relapse [1-5]. Allogeneic hematopoietic

stem cell transplantation (allo-SCT) has been widely used as postremission therapy, especially for patients with high-risk ALL [6-8]. Even in patients treated with allo-SCT using a standard regimen of cyclophosphamide with total-body irradiation (CY/TBI), relapse has been a significant cause of death [7-12]. Various

intense conditioning regimens, including some regimens using VP-16 (VP) combined with CY/TBI (VP/CY/TBI), have therefore been developed [13-21]. The use of some intense regimens resulted in better disease control, but higher rates of toxicity and transplant-related mortality (TRM) have also been reported. We speculated that the high rates of TRM in these studies were mainly due to the doses of VP (45-60 mg/kg). Recently, we reported successful outcomes of patients with various kinds of hematologic malignancies treated with a medium-dose VP (30 mg/kg)/CY/TBI regimen at Hokkaido University Hospital in Japan: all of the 11 patients with adult ALL were alive after a median follow-up period of 77.0 months, and the actuarial 5-year disease-free survival (DFS) rate was 100% [22].

In this retrospective study, we confirmed the safety and efficacy of the medium-dose VP/CY/TBI regimen for 37 patients with adult and adolescent ALL or related disorders and revealed suitable patients for this regimen.

PATIENTS AND METHODS

Patients

We studied outcomes in a consecutive series of 37 adult or adolescent patients diagnosed with ALL, acute biphenotypic leukemia (ABL), or T cell lymphoblastic lymphoma (T-LBL) who underwent allo-SCT using a conditioning regimen of medium-dose VP/CY/TBI during the period from 1993 to June 2007 at Hokkaido University Hospital. We have been using this regimen for all adult ALL patients without any intentional selection, and all of the patients in whom this regimen was used were included in this study. Data for patients with Burkitt leukemia (FAB classification: L3) were excluded from analysis because Burkitt leukemia is defined as a different category from ALL in the World Health Organization (WHO) classification. Almost all of the patients received multiagent chemotherapies (CY, vincristine, doxorubicin, L-asparaginase, and glucocorticoid) as an induction therapy, and 7 of the 10 Philadelphia chromosome-positive (Ph⁺) patients were treated with chemotherapies that included imatinib prior to allo-SCT. No patient was exposed to VP as an induction therapy, but 15 patients received 1 course of consolidation therapy that included VP at a dose of 100 mg/m² daily for 4 or 5 days (total dose: 400 mg/m² or 500 mg/m²).

Conditioning Regimen

All patients received medium-dose VP/CY/TBI. This regimen consisted of VP at a dose of 15 mg/kg once daily administered intravenously (i.v.) on days -7 and -6 (total dose: 30 mg/kg) and CY at 60 mg/kg once daily i.v. on days -5 and -4 (total dose: 120 mg/kg) combined with fractionated TBI at 2 Gy twice daily on days -3 to -1 (total dose: 12 Gy). Until 2000,

graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine A and a short course of methotrexate (MTX, 15 mg/m² on day 1 and 10 mg/m² on days 3 and 6) for all of the patients. Since 2001, cyclosporine A plus MTX has been given for HLA-matched related donor (MRD) recipients and tacrolimus plus a short course of MTX has been given for HLA-matched unrelated donor (MUD) or HLA-mismatched donor (MMD) recipients. GVHD prophylaxis was administered for 3 months and then tapered in patients with no active GVHD, and the dose of cyclosporine A or tacrolimus was adjusted by plasma level.

Supportive Care

Granulocyte colony-stimulating factor was administered from day 1 until engraftment. A standard regimen of antibiotic prophylaxis was used to prevent bacterial, viral, fungal, and *Pneumocystis jirovecii* infections. Treatment of mucosal injury and neutropenic fever was performed in accordance with standard practice guidelines. Surveillance blood antigenemia for cytomegalovirus was monitored twice weekly between engraftment and day 100 post-SCT, and patients received preemptive ganciclovir at onset of cytomegalovirus antigenemia.

Evaluation of Response

In this study, high-risk ALL patients were defined as those with at least 1 of the following risk factors: Ph⁺, ABL, age ≥ 35 years old, white blood count (WBC) $>3.0 \times 10^{10}/L$ for B lineage and $>10 \times 10^{10}/L$ for T lineage at diagnosis, and time to CR of >6 weeks. Patients with T-LBL were excluded from this risk stratification. Neutrophil engraftment and platelet engraftment were defined as the first of 2 days with absolute neutrophil count $>0.5 \times 10^9/L$ and the first of 7 days with an untransfused platelet count $>50 \times 10^9/L$, respectively. Toxicity after SCT was graded by the National Cancer Institute (NCI) common toxicity criteria (NCI, Bethesda, MD). Acute GVHD (aGVHD) and chronic GVHD (cGVHD) were graded by standard criteria. Serial samples of peripheral blood or bone marrow were monitored for hematopoietic chimerism by using polymerase chain reaction (PCR)-based analyses of short tandem repeats. In some patients, minimal residual disease was assessed by using the PCR method for detecting *BCR-ABL* fusion gene or case-specific immunoglobulin heavy chain or T cell receptor rearrangement, as described previously [23]. In brief, bone marrow samples were collected at the time of initial diagnosis and DNA was extracted. DNA samples were amplified by the seminested PCR procedure using amplimers for clonal VH-JH for IgH, V γ -J γ for TCR γ , and nested PCR detecting each VDJ δ 1-TCR recombination and V δ 2-D δ 3 recombination for TCR δ gene rearrangements.

For the detection of residual leukemic cells in specimens from patients, genomic DNA from leukemic cells at the time of initial diagnosis was compared with that from leukemic cells obtained before and after SCT.

Statistical Analysis

Overall survival (OS) was calculated from the day of SCT until death or last follow-up. The probability of OS was estimated using the Kaplan-Meier method. Relapse and TRM rates were estimated using cumulative incidence analysis and considered as competing risks. The effects of various patient and disease categorical variables on survival probabilities were studied using the log-rank test. All *P*-values were 2-sided and a *P*-value of .05 was used as the cutoff for statistical significance.

RESULTS

Patients and Transplant Characteristics

Patients and transplant characteristics are summarized in Table 1. The median age of the patients was 26 years (range: 15-58 years). Twenty-eight (75.7%) of the patients had ALL (B cell: 64.9%, T cell: 10.8%), 4 (10.8%) had ABL and 5 (13.5%) had T-LBL. Cytogenetic study was performed in 31 patients (83.8%) at diagnosis and Ph was positive in 10 (32.3%) of those patients. Twenty-one (68.8%) of the 32 evaluable patients were at high risk: age >35 years (13 patients, 35.1%), Ph⁺ (mentioned above), ABL (4 patients, 12.5%), WBC >3.0 × 10¹⁰/L for B lineage at diagnosis (6 patients, 18.8%) and time to CR >6 weeks (7 patients, 21.9%). Central nervous system involvement of leukemia during the course of disease was seen in 3 patients (8.1%). Thirty-five (94.6%) of the patients were in CR at the time of SCT, 75.7% in first CR (CR1), and 18.9% in second CR (CR2). Only 2 patients were not in CR (non-CR). The *BCR-ABL* fusion gene was undetectable in 4 Ph⁺ patients at the time of transplant. Patients received allo SCT from an MRD (13 patients, 35.1%), MUD (18 patients, 48.6%), or MMD (6 patients, 16.2%), and 32 patients (86.5%) received bone marrow.

Engraftment

All patients engrafted with median neutrophil recovery at day 16 (range: 8-25 days) and 34 patients engrafted with median platelet recovery at day 27 (range: 18-74 days). Results of engraftment analysis using short tandem repeats were available for 20 patients, showing 100% donor chimerism in all of them with median time of 100% chimerism being day 28 (range: 12-49 days). No recipient developed secondary graft failure.

Table 1. Patient and Transplant Characteristics

	n (%)
Total	37
Median age (range)	26 (15.58)
Age ≥ 35	13 (35.1%)
Age ≥ 40	7 (18.9%)
Sex	
Male	20 (54.1%)
Female	17 (45.9%)
Diagnosis	
B-ALL	24 (64.9%)
T-ALL	4 (10.8%)
ABL	4 (10.8%)
T-LBL	5 (13.5%)
Philadelphia chromosome*	10 (32.3%)
WBC >3 × 10¹⁰ for B-ALL†	6 (18.8%)
WBC >10 × 10¹⁰ for T-ALL†	0 (0.0%)
Time to CR >6 weeks†	7 (21.9%)
Disease risk†	
Standard	10 (31.3%)
High	22 (68.8%)
CNS involvement during course	3 (8.1%)
Disease status at transplantation	
CR	35 (94.6%)
CR1	28 (75.7%)
CR2	7 (18.9%)
non-CR	2 (5.4%)
Minimal residual disease at transplantation in CR patients	
PCR ⁺	11 (31.4%)
PCR ⁻	9 (25.7%)
N.D.	15 (42.9%)
Donor	
MRD	13 (35.1%)
MUD	18 (48.6%)
MMRD	2 (5.4%)
MMUD	4 (10.8%)
Stem cell source	
Bone marrow	32 (86.5%)
Peripheral blood stem cell	4 (10.8%)
Cord blood	1 (2.7%)
GVHD prophylaxis	
CSP+MTX	28 (75.7%)
TK+MTX	9 (24.3%)

All indicates acute lymphoblastic leukemia; ABL, acute biphenotypic leukemia; T-LBL, T cell lymphoblastic lymphoma; MRD, matched related donor; MUD, matched unrelated donor; MMD, mismatched donor; CR, complete remission; WBC, white blood cell; MMRD, mismatched related donor; MMUD, mismatched unrelated donor.

*Cytogenetic study was performed in 31 patients.

†Five patients with T-LBL were excluded from risk stratification.

Disease Control

Posttransplant bone marrow studies were not performed in 2 patients because of early deaths. None of the remaining 35 patients showed evidence of residual disease by morphology or cytogenetics. In 11 patients with morphologic CR but with minimal residual disease (PCR⁺ CR) at the time of transplant, 10 patients (90.9%) became PCR-negative (PCR⁻ CR) after transplant and the remaining patient had persistent PCR positivity with no relapse. All Ph⁺ patients were




Figure 1. Cumulative incidence of relapse (a), TRM (b), and OS (c). TRM indicates transplant-related mortality; OS, overall survival.

alive without relapse during the follow-up period, and all of the 6 Ph⁺ patients who were PCR-positive at transplantation became PCR-negative after allo-SCT. Therefore, no patients received imatinib after SCT. Only 3 patients (8.1%) relapsed after allo-SCT on days 95, 113, and 564, respectively, and all of them died (Figure 1a). Two of the 3 patients with earlier relapse had T-LBL and the other had B-ALL. These patients were in PCR CR1 at transplantation, and 2 (40%) of the 5 T-LBL patients relapsed.

Toxicity and GVHD

Table 2 shows a summary of organ toxicity and GVHD. Toxicity before engraftment could be assessed in 33 patients but not in 4 patients because of insufficient medical records. NCI grade ≥ 3 nonhematologic

Table 2. Organ Toxicities and GVHD

	No (%)
Organ toxicity*	
Any grade 3 toxicity	27 (81.8%)
Stomatitis	19 (57.6%)
Diarrhea	11 (33.3%)
Cardiovascular	2 (6.1%)
Pulmonary/DAH	1 (3.0%)
Hepatic	3 (9.1%)
VOD	2 (6.1%)
TMA	2 (6.1%)
Death due to organ toxicity	2 (5.4%)
Febrile episode before engraftment	23 (69.7%)
GVHD†	
Acute GVHD total	29 (78.4%)
Acute GVHD grade II-IV	15 (40.5%)
Chronic GVHD total	18 (54.5%)
Chronic GVHD extensive	12 (36.4%)
Death due to GVHD	0 (0.0%)

DAH indicates diffuse alveolar hemorrhage; VOD, veno-occlusive disease of the liver, TMA, thrombotic microangiopathy.

*Toxicity is graded by NCI common toxicity criteria. Only patients with grade 3 toxicity are presented. Some patients had toxicity in more than one organ system. Organ toxicity was evaluated in 33 patients.

†Acute GVHD and chronic GVHD were evaluated in 37 and 33 patients, respectively.

organ toxicity occurred in 27 patients (81.8%). NCI grade 3 stomatitis and diarrhea were common findings, occurring in 19 patients (57.6%) and 11 patients (33.3%), respectively. Febrile episodes were also common during the neutropenic period, occurring in 23 patients (69.7%). Although blood cultures and chest X-rays were frequently performed, pathogens of the fever could be detected in only 4 patients. Cardiovascular toxicity (congestive heart failure), pulmonary toxicity, hepatic toxicity including veno-occlusive disease (VOD) and transplant-related thrombotic microangiopathy occurred in 2 patients (6.1%), 1 patient (3%), 3 patients (9.1%), and 2 patients (6.1%), respectively. A clinical diagnosis of VOD could be made by the Jones criteria in only two patients (6.1%), and 1 of them, who had active disease at transplantation, died of hepatic failure on day 27. One patient of relatively advanced age (58 years old) died of respiratory failure due to interstitial pneumonitis of unknown etiology on day 48. Total and grade II-III aGVHD occurred in 29 and 15 patients with cumulative incidences of 78.4% and 40.5%, respectively. No patient developed grade IV aGVHD. Median onset day of aGVHD was day 19 (range: 7-59 days). Chronic GVHD occurred in 18 of the 33 evaluable patients, extensive in 12 patients, and limited in 6 patients (cumulative incidence: 54.5%), at median day 118 (range: 48-254 days). No patient died of complications related to aGVHD or cGVHD, and no secondary malignancy was observed during the follow-up period. TRM occurred in only 2 patients with a cumulative incidence of 5.4% at 3 years after SCT (Figure 1b).

Survival

At the end of a median follow-up period of 35.1 months (range: 0.9-163.2 months), 32 patients were alive and 5 had died. Two patients died of treatment-related complications before day 100 and 3 patients died of disease relapse. The actuarial 3-year OS and 5-year OS rates were 89.2% and 86.5%, respectively (Figure 1c). The 3-year OS rates for allo-SCT at CR1, CR2, and non-CR were 92.6%, 85.7%, and 50%, respectively. OS rates were 92.9% for patients with ALL, 100% for those with ABL, and 60% for those with T-LBL. All Ph⁺ patients were alive and OS rate was 83.3% for those without Ph. OS rates for patients with aGVHD and those without aGVHD were 93.1% and 75.1%, respectively, and OS rates for patients transplanted from MRDs and those from MUDs were 76.9% and 100%, respectively. Table 3 shows the results of univariate analysis of factors influencing OS. Univariate analysis revealed non-CR at transplantation ($P < .01$), MRD ($P = .01$) and no aGVHD ($P = .02$) to be significant adverse prognostic factors for OS. Although not statistically significant, diagnosis of T-LBL ($P = .06$) or no cGVHD ($P = .08$) tended to have an adverse impact on OS. Age, patient's sex, central nervous system involvement, disease risk, type of CR (CR1 or CR2, PCR⁺ or PCR⁻) and GVHD prophylaxis were not predictive factors for the outcome.

DISCUSSION

We have previously reported the safety and efficacy of medium-dose VP/CY/TBI as a conditioning regimen of allo-SCT for hematologic malignancies [22]. In the current study, focusing on adult patients with ALL, engraftment was achieved in all patients. Although grade 3 stomatitis and febrile episodes in the neutropenic period were common, severe GVHD and TRM were not increased compared with those in previous studies [7-12]. The 3-year OS of 89.2% in our case series compares favorably with the results of other studies using a standard conditioning regimen of CY/TBI [7-12], our good results being because of reduction in relapse. In the LALA-94 trial, patients in CR1 with MRD were allocated to allo-SCT using CY/TBI. In the patients treated with allo-SCT, 3-year TRM rate, 3-year relapse rate, and 3-year disease-free survival (DFS) rate were 18%, 34%, and 47% respectively [10], indicating that relapse was the main cause of death even after allo-SCT. There have been many reports on intensified conditioning regimens of allo-SCT including high-dose VP (60 mg/kg or 1.5-1.8 g/m²)/CYTBI for the purpose of reduction in relapse rate [13-22]. Most of those studies using VP/CY/TBI included patients with various kinds of hematologic malignancy, but our study was limited to adult ALL. In our study, relapse occurred in only 3 patients

(8.1%), indicating much better disease control than that of CY/TBI or other regimens. Although our patients with GVHD showed better outcome than those without GVHD, which may suggest a graft-versus-leukemia (GVL) effect, better disease control in this study was thought to be mainly due to eradication of residual disease by the conditioning regimen. The reasons are that GVL effect has been reported to have limited efficacy for ALL patients, occurrence of aGVHD or cGVHD in our study was the same as that in other studies, and PCR⁺ CR patients at transplantation became PCR⁻ CR soon after allo-SCT, suggesting a direct antitumor effect of the conditioning regimen. Although Ph⁺ patients have been reported to have a poorer outcome than that of Ph⁻ patients after allo-SCT [10,24,25], all Ph⁺ patients in our study were alive without relapse. Furthermore, some studies have shown that the outcome for patients in CR2 at transplantation was worse than that for patients in CR1 [26-28], but the outcomes of patients in CR1 and CR2 in the present study were comparable. Marks et al. [29] reported that a VP/TBI regimen showed better disease control than that of standard-dose CY/TBI for patients with ALL in CR2, indicating that VP has better anti-ALL activity than that of CY.

The rate of TRM in this study was also very low, occurring in only two patients (5.3%), and no patient died before engraftment despite the high rate of mucosal injury or febrile episodes. Furthermore, although there have been reports that aGVHD is related in part to cytokine release from damaged gastrointestinal tissues, incidence and severity of aGVHD in this study did not increase, and no patient died of GVHD. The dose used in VP/CY/TBI regimens in previous studies (60 mg/kg or 1.5-1.8 g/m²) was higher than that used in our regimen, and the rate of TRM was higher in those studies (28%-47%), pulmonary toxicity (pulmonary hemorrhage and interstitial pneumonitis), and liver toxicity including VOD being the main causes of death [13-22]. Giralt et al. [14] and Yau et al. [16] reported that rates of TRM were 32.9% and 27.9%, respectively, and that incidences of diffuse alveolar hemorrhage causing death were 8% and 7%, respectively. In our study, only 1 patient (58 years old) died of interstitial pneumonitis, and no patient experienced diffuse pulmonary hemorrhage. Three patients developed grade 3 liver toxicity and 2 of them had VOD, and 1 of them with active disease died of hepatic failure due to VOD. Peterson et al. [15] and Spitzer et al. [20] reported that a lower dose of VP was associated with reduction in TRM, and we speculated that the difference between TRM in our study and that in other studies using VP/CY/TBI is mainly because of the dose of VP [22]. Although the dose of VP seemed to be important, TRM of 5.8% in this study was unexpectedly low. We have used a medium-dose VP/CY/TBI regimen for a total 92 patients with various kinds of hematologic

Table 3. Univariate Analysis of Factors Predicting for Overall-Survival after allo-SCT

	n	Alive (%)	HR	(95%CI)	P-value*
Age					
<40	30	27 (90.0%)	0.79	(0.07-8.25)	0.83
≥40	7	6 (85.7%)			
Sex					
Male	20	18 (90.0%)	0.59	(0.10-3.41)	0.55
Female	17	14 (82.4%)			
Diagnosis					
non T-LBL ALL	28	25 (89.3%)	0.21	(0.01-1.10)	0.06
ABL	4	4 (100%)			
T-LBL	5	3 (60.0%)			
Philadelphia chromosome					
Yes	10	10 (100%)	0.00	(0.04-1.68)	0.15
No	24	19 (79.2%)			
Disease risk					
Standard	10	9 (90.0%)	0.82	(0.07-8.95)	0.87
High	22	20 (90.9%)			
CNS involvement during course					
Yes	3	2 (66.7%)	1.17	(0.21-152.93)	0.30
No	34	30 (88.2%)			
Disease status at transplantation					
non-CR	2	1 (50.0%)	10.90	(9.78-1.5×10 ⁶)	<0.01
CR	35	31 (88.6%)			
CR1	28	25 (89.3%)	0.79	(0.07-8.69)	0.83
CR2	7	6 (85.7%)			
PCR+CR	9	8 (88.9%)	1.17	(0.07-19.09)	0.91
PCR-CR	11	10 (90.9%)			
Donor					
MUD	13	13 (100%)	0.00	(0.01-0.61)	0.01
MRD	18	14 (77.8%)			
Acute GVHD prophylaxis					
CSP+MTX	28	24 (85.7%)	1.00	(0.11-9.03)	1.00
TK+MTX	9	8 (88.9%)			
Acute GVHD					
Yes	29	27 (93.1%)	0.15	(0.01-0.62)	0.02
No	8	5 (62.5%)			
Chronic GVHD					
Yes	18	18 (100%)	0.00	(0.00-1.37)	0.08
No	15	13 (86.7%)			

HR indicates hazard ratio; 95%CI, 95% confidence interval.
*Statistical analysis on OS was studied with the log-rank test.

malignancy and TRM rate was 15.2% (data not shown). Risk factors for TRM in this population were age ≥40 years (age <40 years: 8.7% versus age ≥40 years: 33.3%, $P = .001$) and non-CR at transplantation (CR: 10.8% versus non-CR: 25.9%, $P < .001$). Duerst et al. [21] reported that older age and advanced disease at transplantation were the main risk factors for TRM in their analysis of allo-SCT using medium-dose VP/CY/TBI for children with acute leukemia. In the current study, a smaller number of patients had these risk factors: 7 patients (19%) were older than 40 years and 2 patients (6%) were not in CR at transplantation, accounting for the unexpectedly low rate of TRM. The younger age of our patients may also explain our good results because of excellent disease control. Many clinical trials have shown higher remission rate and better prognosis among younger patients because of different biologic characteristics of leukemic cells and lower rate of complications despite intensified chemotherapy

[30-33]. In our study, among 23 patients under the age of 30 years, 16 patients (69.6%) received SCT in CR1 and only 2 patients died due to disease progression. Two of the 3 patients with Ph were treated with imatinib before SCT, and 3 very young patients (<25 years of age) were treated using an intensified regimen like that used for childhood ALL. Nine patients received consolidation chemotherapies, which included high-dose cytarabine and high-dose MTX, and no patients developed central nervous system leukemia during the follow-up period. These developments in treatment strategy before SCT may also have contributed to the good results of our study.

A special consideration when using VP is secondary malignancies. Although VP is an active agent in ALL, many studies, mostly conducted in pediatric centers, have shown an increased risk of therapy-related leukemia and other malignancies by using VP [34-35], and VP has therefore been removed from most